Neurotech International Share Price and Company Fundamentals
Last traded: Today at 11:24 PM
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome. It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains. The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
-
Dividend yield
0.00%
Beta
-0.03
Market cap
$25.13M
Enterprise value
$22.75M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://neurotechinternational.com |
| Mailing address | 55 Collins Street Suite 102 Level 1 Melbourne VIC 3000 Australia |
| Phone / Fax | 61 3 9498 3132 / 61 8 9489 3132 |
Dividends
More: Neurotech International Dividend history, yield and payout ratio
Dividend yield
0.00%
Dividend amount
$-
Payout ratio
-
5Y Avg. yield
-%
Neurotech International paid $- dividend and the ex-dividend date was -.The dividend payout ratio is -. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.
Company Executives
As of Nov 2026, following are the company executives and directors listed on Neurotech International.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Mark Davies | Executive Chairman | ||
| Associate Prof. Carolyn Ellaway | Chief Medical Officer | ||
| Dr. Bonni Goldstein M.D. | Chief Medical Advisor for USA | 61 | |
| Mr. Peter James Lawrence Griffiths B.Sc. | Chief Executive Officer of AAT Research Ltd | 61 | |
| Ms. Alessandra Marie Gauvin | Company Secretary |
Profitability and management effectiveness
Profit margin
-138.11%
Operating margin
-139.65%
Return on assets
-138.02%
Return on equity
-366.75%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Neurotech International is 25.13M and its enterprise value is 22.75M. The enterprise value to revenue ratio of NTI is 4.80. The enterprise value to EBITDA ratio of NTI is -3.44.
Companies similar to Neurotech International (NTI)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Pro Medicus (PME)
- Polynovo (PNV)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Neurotech International (ASX:NTI) Frequently Asked Questions
1. What is Neurotech International's Stock Symbol?
Neurotech International trades on ASX under the ticker symbol "NTI".
2. What is Neurotech International's stock price today?
One share of NTI stock can currently be purchased for approximately $0.019.
3. How can I contact Neurotech International?
Neurotech International's mailing address is 55 Collins Street Suite 102 Level 1 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9498 3132.
4. What is Neurotech International's official website?
The official website of Neurotech International is https://neurotechinternational.com.